ClinicalTrials.gg
RecruitingNCT07570654RedefineUpdated Nov 12, 2026

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

A Phase 2/3 interventional study of COMP360 psilocybin in PTSD - Post Traumatic Stress Disorder, PTSD and PTSD Symptoms, sponsored by COMPASS Pathways. Recruiting at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by COMPASS Pathways · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 12, 2026First site in CanadaStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Combat Disorders with a site in United States — 41 open to participants now, 44 under way, 2 of them phase 3. Combat Disorders · United States.

Planned enrollment
10th of 100
300 · median 74
Started
2026
with 21 others
Phase 2/3
3 of 114
1 open now
Primary completion
2028-11
later than 28 of 43 live
Registered
101st of 114
by date

Among the 114 studies in Combat Disorders with a site in United States, this one is the 10th largest by planned enrollment of the 100 interventional ones that give a count, is one of 22 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 28 of the 43 other live ones, and was the 101st registered.

Combat Disorders

203 studies on the registry are indexed under Combat Disorders; 92 are open to participants now.

Browse Combat Disorders studies →

Open to participants now

41 of the 114 studies in Combat Disorders with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Combat Disorders studies recruiting now, 21 (40%) set no upper age limit and 26 (50%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Combat Disorders with a site in United States, or all of them as a file.
02

Study summary

The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.

03

Conditions studied

  • PTSD - Post Traumatic Stress Disorder
  • PTSD
  • PTSD Symptoms
  • PTSD, Post Traumatic Stress Disorder

Keywords

  • COMP360
  • psilocybin
  • Redefine
  • PTSD
  • trauma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Diagnosed with PTSD at least 6 months ago

Exclusion criteria

Exclusion Criteria:

- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    1 mg COMP360 psilocybin

    Drug: COMP360 psilocybin

  • Experimental
    10 mg COMP360 psilocybin

    Drug: COMP360 psilocybin

  • Experimental
    25 mg COMP360 psilocybin

    Drug: COMP360 psilocybin

Interventions

06

What researchers measure

Primary outcomes

  1. COMP360 25 mg versus COMP360 1 mg change from Baseline to Week 8 in CAPS-5 total severity score

    The CAPS-5 (Clinician-Administered PTSD Scale for DSM-5) is a 30-item structured interview that yields a total severity score (0-80) reflecting PTSD symptoms. A higher CAPS-5 score indicates more severe, intense, and frequent PTSD symptoms.

    Time frame: 8 weeks

07

Study locations

20 of 20 sites recruiting
  • AZ
    Tucson, Arizona 85704, United States
    Recruiting
  • CA
    Irvine, California 92612, United States
    Recruiting
  • CA
    Los Angeles, California 90025, United States
    Recruiting
  • CA
    Moorpark, California 93021, United States
    Recruiting
  • CA
    San Jose, California 95124, United States
    Recruiting
  • FL
    Miami, Florida 33125, United States
    Recruiting
  • FL
    Orlando, Florida 32801, United States
    Recruiting
  • IL
    Chicago, Illinois 60612, United States
    Recruiting
  • MA
    Boston, Massachusetts 02116, United States
    Recruiting
  • MN
    Eden Prairie, Minnesota 55347, United States
    Recruiting
  • NE
    Lincoln, Nebraska 68526, United States
    Recruiting
  • NV
    Las Vegas, Nevada 89119, United States
    Recruiting
  • NY
    New York, New York 10025, United States
    Recruiting
  • NY
    The Bronx, New York 10461, United States
    Recruiting
  • OH
    North Canton, Ohio 44720, United States
    Recruiting
  • TX
    Carrollton, Texas 75010, United States
    Recruiting
  • UT
    Orem, Utah 84058, United States
    Recruiting
  • BC
    Kamloops, British Columbia V2C 5T1, Canada
    Recruiting
  • BC
    North Vancouver, British Columbia V7P2T4, Canada
    Recruiting
  • BC
    Penticton, British Columbia V2A5L5, Canada
    Recruiting
08

References and documents

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Nov 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 6, 2026
StartActual
Sep 14, 2026
Primary completionEst.
Nov 2028
CompletionEst.
Sep 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
19 sites added, 1 site removed — first site in Canada
Show 19 added (16 United States, 3 Canada)
  • FL · Miami, United States
  • FL · Orlando, United States
  • NE · Lincoln, United States
  • IL · Chicago, United States
  • MN · Eden Prairie, United States
  • NV · Las Vegas, United States
  • BC · North Vancouver, Canada
  • NY · The Bronx, United States
  • AZ · Tucson, United States
  • CA · Irvine, United States
  • CA · Los Angeles, United States
  • CA · Moorpark, United States
  • MA · Boston, United States
  • OH · North Canton, United States
  • TX · Carrollton, United States
  • BC · Kamloops, Canada
  • CA · San Jose, United States
  • UT · Orem, United States
  • BC · Penticton, Canada
Show 1 removed
  • Florida · Orlando, United States
across 6 updates, Oct 1, 2026 – Nov 12, 2026
Contact
Study contact changed: T•••@compasspathways.com · •••9258→T•••@compasspathways.com · •••9258. See the current contact
Oct 23, 2026
Show all 6 updates
  1. Nov 12, 2026
    3 sites added
    Show 3 added (2 United States, 1 Canada)
    • CA · San Jose, United States
    • UT · Orem, United States
    • BC · Penticton, Canada
  2. Nov 5, 2026
    7 sites added
    Show 7 added (6 United States, 1 Canada)
    • CA · Irvine, United States
    • CA · Los Angeles, United States
    • CA · Moorpark, United States
    • MA · Boston, United States
    • OH · North Canton, United States
    • TX · Carrollton, United States
    • BC · Kamloops, Canada
    + 1 other change: date precision
  3. Oct 23, 2026
    1 site added
    Show site
    • AZ · Tucson, United States
    Contact Study contact changed: T•••@compasspathways.com · •••9258→T•••@compasspathways.com · •••9258. See the current contact
  4. Oct 21, 2026
    1 site added
    Show site
    • NY · The Bronx, United States
  5. Oct 6, 2026
    4 sites added — first site in Canada
    Show 4 added (3 United States, 1 Canada)
    • IL · Chicago, United States
    • MN · Eden Prairie, United States
    • NV · Las Vegas, United States
    • BC · North Vancouver, Canada
  6. Oct 1, 2026
    3 sites added, 1 site removed
    Show 3 added (3 United States)
    • FL · Miami, United States
    • FL · Orlando, United States
    • NE · Lincoln, United States
    Show 1 removed
    • Florida · Orlando, United States
    + 1 other change: references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07570654
Lead sponsor
COMPASS Pathways
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Sep 14, 2026
Primary completion
Nov 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

www.redefineptsdstudy.com Redefine Study Call Center
Contact
TheRedefineStudy@compasspathways.com
202-459-9258

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion